IOVA

Business Context and Reporting Period

Company: Genesis Biopharma, Inc. (Note: Metadata listed "IOVANCE BIOTHERAPEUTICS, INC." but the filing text identifies the registrant as Genesis Biopharma, Inc.)
Reporting Period: Quarter and six months ended June 30, 2012.
Status: Development stage company with no revenue-generating operations. The company pivoted from freight management to biopharmaceuticals in 2010 and is currently developing "Contego," an adoptive cell therapy for metastatic melanoma, under license from the National Institutes of Health (NIH).

Key Financial Metrics

Debt Obligations:

• 12% Secured Promissory Notes: $1,216,250 outstanding (extended to Sept 30, 2012). Secured by a first priority lien on all assets.
• 7% Convertible Promissory Notes: $5,000,000 outstanding (extended to Nov 30, 2012). Can be called for payment at any time.
• Derivative Liabilities: $8,740,110 (fair value of warrants and conversion features).
• Accrued NIH Expenses: $616,000.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss for the six months ended June 30, 2012 ($6.1M) decreased significantly compared to the same period in 2011 ($11.5M). This was primarily driven by a reduction in non-cash stock-based compensation expenses ($1.7M in 2012 vs. $9.3M in 2011).
• Derivative Liability Gain/Loss: The company recorded a gain of $1.9M on the change in fair value of derivative liabilities for the quarter ended June 30, 2012, compared to a loss of $0.4M in the prior year quarter. This gain was largely due to a decrease in the company's stock price used in valuation models.
• Debt Structure: The company issued $1.2M in new secured promissory notes during the period, replacing earlier short-term notes. The 2011 Convertible Notes ($5M) remain outstanding but have been extended multiple times.
• Cash Position: Cash and cash equivalents dropped from $510,217 at December 31, 2011, to $15,739 at June 30, 2012, reflecting a net cash outflow from operating activities of $1.96M.

Outlook, Risks, and Management Commentary

Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. The company has minimal cash ($15,739) and no revenue. It requires significant additional capital to fund operations and repay debt.

Liquidity Crisis:

• The company does not have sufficient funds to repay the $1.2M secured notes (due Sept 30, 2012) or the $5M convertible notes (due Nov 30, 2012).
• Failure to repay the secured notes could result in foreclosure of all company assets.
• The company cannot fund upcoming NIH payments ($250k quarterly installment due Sept 5, 2012, and $616k accrued expenses due Aug 27, 2012) without new financing.

Future Funding Needs: Management estimates a need for over $35 million over the next 12 months to develop the Contego program. No commitments for future financing have been identified.

Internal Controls: The company disclosed a material weakness in internal controls over financial reporting due to a lack of segregation of duties and expertise in accounting for complex transactions.

Investor Verification Checklist

• Debt Maturity Dates: Verify the status of the $1.2M secured notes (due Sept 30, 2012) and $5M convertible notes (due Nov 30, 2012) and whether further extensions have been granted.
• Cash Runway: Confirm current cash balance and ability to meet immediate NIH payment obligations due in August and September 2012.
• Financing Plans: Assess the likelihood of securing the estimated $35M needed for operations, given the lack of current commitments.
• Asset Security: Note that the secured notes carry a first priority lien on all assets, meaning equity holders could lose everything in a foreclosure scenario.
• Derivative Liability Volatility: Monitor the fair value of derivative liabilities ($8.7M), which fluctuates with stock price and volatility, significantly impacting reported net income/loss.